Sign Up to like & get
recommendations!
0
Published in 2018 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-018-6795-9
Abstract: PurposeClopidogrel is the standard P2Y12 receptor inhibitor used in patients requiring both antiplatelet therapy and oral anticoagulation (OAC). We investigated the safety and efficacy of ticagrelor as an alternative to clopidogrel in patients on OAC.MethodsA…
read more here.
Keywords:
dual triple;
ticagrelor;
triple antithrombotic;
versus ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Progress in cardiovascular diseases"
DOI: 10.1016/j.pcad.2021.11.010
Abstract: Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel forms the backbone of secondary prevention in patients with acute coronary syndromes (ACS) or who undergo percutaneous coronary intervention (PCI), but in patients with atrial fibrillation (AF),…
read more here.
Keywords:
percutaneous coronary;
therapy;
coronary intervention;
triple antithrombotic ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz745.1017
Abstract: Triple antithrombotic therapy (TAT) is known to increase bleeds and its relevance is questioned. No study has observed the long-term risk of bleeding and health care costs from a sex perspective, in a total TAT…
read more here.
Keywords:
health care;
care costs;
triple antithrombotic;
term risk ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15257
Abstract: A 78-year-old woman with atrial fibrillation (AF) and hypertension presented to the emergency department with chest pain. Her medications include amlodipine 5 mg once daily and apixaban 5 mg twice daily. The admission ECG demonstrated…
read more here.
Keywords:
triple antithrombotic;
therapy;
dual therapy;
therapy evidence ... See more keywords